Lupin subsidiary MedQuímica buys rights to nine drugs from Bausch Health

Lupin Limited said that MedQuímica Indústria Farmacêutica, its 100% subsidiary in Brazil, has agreed to acquire all rights to nine drugs from Bausch Health Companies’ subsidiary BL Indústria Ótica.

The financial terms of the deal were not disclosed.

Through the deal, MedQuímica will gain rights to the three central nervous system drugs — Limbitrol, Melleril, and Dalmadorm, five topical oncological treatments — Bacrocin, Solaquin, Glyquin, Efurix, and Oxipelle, and Wilson’s disease drug Cuprimine.

Alexandre Franca — MedQuímica Managing Director said: “The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness.

“This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market.”